The Inflation Reduction Act (IRA) has caused strong disruption to innovation in drug development, and this impact is falling heaviest on oncology and neuroscience. Cancer drug development has been remarkably productive in embracing a precision medicine and targeted therapy approach to approvals and adoption of new drugs. Neuroscience will also follow a similar path. While there have been many discussions from policy leaders and the pharmaceutical industry, what has been missing is a clear discussion with practicing clinicians and patients about the actual impact of the IRA. This session is an opportunity to hear directly from some of the most highly regarded clinicians as well as the patient perspective about how policy is impacting oncology, neurosciences, and the adoption of novel therapies. The viewpoints are the personal views of these clinicians, and not their institutions, and the audience will learn more about the real world practice of bringing transformational new drugs to patient care.